Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Neoplasms | 11 | 2022 | 212 | 5.700 |
Why?
|
| Ovarian Neoplasms | 10 | 2022 | 723 | 2.970 |
Why?
|
| Endometrial Neoplasms | 5 | 2023 | 189 | 2.840 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2023 | 43 | 2.740 |
Why?
|
| Biomarkers, Tumor | 13 | 2022 | 1450 | 2.720 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 5 | 2022 | 16 | 2.660 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 3 | 2021 | 9 | 2.310 |
Why?
|
| Immunohistochemistry | 14 | 2021 | 1747 | 2.100 |
Why?
|
| DNA Mismatch Repair | 4 | 2023 | 52 | 1.700 |
Why?
|
| Genital Neoplasms, Female | 3 | 2022 | 107 | 1.650 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2021 | 11 | 1.620 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2022 | 62 | 1.620 |
Why?
|
| Myofibroma | 2 | 2020 | 3 | 1.440 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 42 | 1.390 |
Why?
|
| Adenoma | 2 | 2022 | 231 | 1.380 |
Why?
|
| Adnexal Diseases | 2 | 2019 | 17 | 1.260 |
Why?
|
| Carcinoma | 3 | 2022 | 431 | 1.220 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2021 | 54 | 1.180 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 22 | 1.120 |
Why?
|
| Female | 39 | 2023 | 43906 | 1.110 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 6 | 1.060 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2021 | 15 | 1.000 |
Why?
|
| Leiomyoma | 2 | 2017 | 173 | 0.950 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 1155 | 0.930 |
Why?
|
| Broad Ligament | 1 | 2022 | 1 | 0.890 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2022 | 2 | 0.890 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2022 | 7 | 0.890 |
Why?
|
| Ribonuclease III | 2 | 2022 | 14 | 0.880 |
Why?
|
| Leiomyosarcoma | 1 | 2022 | 39 | 0.860 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2022 | 62 | 0.850 |
Why?
|
| Middle Aged | 23 | 2022 | 24747 | 0.840 |
Why?
|
| Krukenberg Tumor | 2 | 2018 | 3 | 0.830 |
Why?
|
| Smooth Muscle Tumor | 1 | 2021 | 4 | 0.830 |
Why?
|
| Adult | 21 | 2022 | 25284 | 0.810 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2020 | 3 | 0.800 |
Why?
|
| Fibronectins | 1 | 2021 | 93 | 0.800 |
Why?
|
| Angiofibroma | 1 | 2020 | 4 | 0.790 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 20 | 0.780 |
Why?
|
| Myxoma | 1 | 2020 | 28 | 0.780 |
Why?
|
| Humans | 40 | 2023 | 84485 | 0.780 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2018 | 348 | 0.780 |
Why?
|
| Polyps | 1 | 2020 | 27 | 0.770 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 30 | 0.760 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 12 | 0.740 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.740 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 126 | 0.720 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1202 | 0.720 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 69 | 0.710 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2018 | 8 | 0.700 |
Why?
|
| Epithelioid Cells | 1 | 2018 | 13 | 0.690 |
Why?
|
| Aged | 15 | 2022 | 18156 | 0.660 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 6 | 0.640 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.640 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 157 | 0.610 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 2845 | 0.590 |
Why?
|
| Progestins | 1 | 2016 | 22 | 0.580 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 52 | 0.570 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 688 | 0.560 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 3 | 0.560 |
Why?
|
| Ovary | 2 | 2021 | 249 | 0.560 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2023 | 33 | 0.560 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2023 | 23 | 0.550 |
Why?
|
| Diagnosis, Differential | 7 | 2022 | 1536 | 0.550 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 28 | 0.550 |
Why?
|
| Ataxia Telangiectasia | 1 | 2015 | 11 | 0.540 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 152 | 0.540 |
Why?
|
| Premenopause | 1 | 2015 | 54 | 0.530 |
Why?
|
| Parotid Gland | 1 | 2015 | 31 | 0.530 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 47 | 0.520 |
Why?
|
| Postmenopause | 1 | 2015 | 95 | 0.510 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 111 | 0.510 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 300 | 0.500 |
Why?
|
| Testosterone | 1 | 2015 | 267 | 0.490 |
Why?
|
| Skin Diseases | 1 | 2015 | 165 | 0.490 |
Why?
|
| Prognosis | 8 | 2022 | 3625 | 0.480 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 346 | 0.480 |
Why?
|
| Young Adult | 6 | 2021 | 5882 | 0.420 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6457 | 0.380 |
Why?
|
| Urethral Stricture | 2 | 2019 | 11 | 0.370 |
Why?
|
| Gene Fusion | 2 | 2020 | 37 | 0.370 |
Why?
|
| Mutation | 4 | 2021 | 3904 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 271 | 0.350 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 169 | 0.320 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 242 | 0.290 |
Why?
|
| Adolescent | 4 | 2021 | 8849 | 0.280 |
Why?
|
| Biopsy | 3 | 2019 | 1143 | 0.280 |
Why?
|
| Cervix Uteri | 3 | 2022 | 61 | 0.260 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1645 | 0.250 |
Why?
|
| Oncogene Fusion | 2 | 2021 | 8 | 0.250 |
Why?
|
| Tissue Array Analysis | 2 | 2021 | 124 | 0.240 |
Why?
|
| Lichen Sclerosus et Atrophicus | 2 | 2019 | 7 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 856 | 0.230 |
Why?
|
| Incidence | 2 | 2019 | 1559 | 0.230 |
Why?
|
| Adenosarcoma | 1 | 2022 | 3 | 0.230 |
Why?
|
| Wolffian Ducts | 1 | 2022 | 7 | 0.220 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 18 | 0.220 |
Why?
|
| Phenotype | 2 | 2019 | 2346 | 0.220 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2022 | 5 | 0.220 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2021 | 8 | 0.210 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 48 | 0.210 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 8 | 0.210 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 13 | 0.210 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2021 | 24 | 0.200 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2021 | 20 | 0.200 |
Why?
|
| Urogenital Neoplasms | 1 | 2021 | 22 | 0.200 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2020 | 4 | 0.200 |
Why?
|
| Genitalia, Female | 1 | 2020 | 25 | 0.200 |
Why?
|
| Vulva | 1 | 2020 | 23 | 0.200 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 128 | 0.200 |
Why?
|
| DNA Helicases | 1 | 2021 | 76 | 0.190 |
Why?
|
| Immunophenotyping | 1 | 2020 | 210 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2249 | 0.190 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2019 | 11 | 0.190 |
Why?
|
| Papillomaviridae | 2 | 2022 | 156 | 0.190 |
Why?
|
| Sarcoma | 1 | 2021 | 210 | 0.180 |
Why?
|
| Urethra | 1 | 2019 | 106 | 0.170 |
Why?
|
| Gene Dosage | 1 | 2019 | 207 | 0.170 |
Why?
|
| Pregnancy | 2 | 2016 | 2820 | 0.170 |
Why?
|
| Mitosis | 1 | 2018 | 149 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8150 | 0.160 |
Why?
|
| Child | 2 | 2020 | 6776 | 0.160 |
Why?
|
| Genomics | 1 | 2023 | 690 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2018 | 280 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 418 | 0.150 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 26 | 0.150 |
Why?
|
| Boston | 1 | 2016 | 32 | 0.150 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 131 | 0.150 |
Why?
|
| Salpingectomy | 1 | 2015 | 3 | 0.140 |
Why?
|
| California | 1 | 2016 | 135 | 0.140 |
Why?
|
| Elastic Tissue | 1 | 2015 | 17 | 0.140 |
Why?
|
| Penicillamine | 1 | 2015 | 12 | 0.140 |
Why?
|
| Voice Disorders | 1 | 2015 | 8 | 0.140 |
Why?
|
| Inflammation | 1 | 2021 | 882 | 0.140 |
Why?
|
| Luteinization | 1 | 2015 | 1 | 0.140 |
Why?
|
| Alopecia | 1 | 2015 | 34 | 0.140 |
Why?
|
| Hirsutism | 1 | 2015 | 61 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2015 | 80 | 0.140 |
Why?
|
| Scleroderma, Systemic | 1 | 2015 | 40 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2015 | 147 | 0.140 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 50 | 0.140 |
Why?
|
| Septum of Brain | 2 | 2005 | 2 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 1929 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2016 | 142 | 0.130 |
Why?
|
| Ovarian Diseases | 1 | 2015 | 32 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 16 | 0.130 |
Why?
|
| Parasympathetic Nervous System | 2 | 2005 | 32 | 0.130 |
Why?
|
| Fibroma | 1 | 2015 | 32 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 123 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2015 | 106 | 0.130 |
Why?
|
| Teratoma | 1 | 2015 | 45 | 0.130 |
Why?
|
| Endometriosis | 1 | 2015 | 57 | 0.130 |
Why?
|
| Estradiol | 1 | 2015 | 246 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2015 | 42 | 0.130 |
Why?
|
| Extremities | 1 | 2015 | 166 | 0.130 |
Why?
|
| Transcription Factors | 1 | 2021 | 1511 | 0.120 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 336 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2667 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 1153 | 0.090 |
Why?
|
| Axotomy | 2 | 2005 | 8 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 5181 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 2005 | 32 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 63 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2401 | 0.060 |
Why?
|
| Polyethyleneimine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Nerve Growth Factor | 1 | 2004 | 17 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2005 | 437 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 152 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 3598 | 0.060 |
Why?
|
| Male | 5 | 2021 | 40457 | 0.060 |
Why?
|
| Biomarkers | 2 | 2019 | 1671 | 0.060 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 15 | 0.050 |
Why?
|
| beta Catenin | 1 | 2022 | 246 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2022 | 526 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 500 | 0.050 |
Why?
|
| Point Mutation | 1 | 2021 | 246 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2019 | 90 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 447 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 846 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 585 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 378 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2016 | 38 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 1128 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2016 | 67 | 0.040 |
Why?
|
| Neurons | 1 | 2004 | 1508 | 0.030 |
Why?
|
| Vagina | 1 | 2016 | 157 | 0.030 |
Why?
|
| Stereotaxic Techniques | 2 | 2005 | 68 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2022 | 2229 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 302 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1205 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 4090 | 0.030 |
Why?
|
| Rats | 2 | 2005 | 3968 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 7829 | 0.020 |
Why?
|
| Fornix, Brain | 1 | 2005 | 2 | 0.020 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2005 | 23 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 265 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 375 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2004 | 72 | 0.020 |
Why?
|
| Transgenes | 1 | 2004 | 179 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 143 | 0.020 |
Why?
|
| Animals | 2 | 2005 | 26197 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 11056 | 0.010 |
Why?
|